A Phase II Trial to Assess the Activity of 17-Allylamino, 17-Demethoxygeldanamycin (17-AAG) in Patients With Metastatic (M1, M1b & M1c) Malignant Melanoma
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2013
At a glance
- Drugs Tanespimycin (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 26 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 26 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.